| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance D Ge, J Fellay, AJ Thompson, JS Simon, KV Shianna, TJ Urban, ... Nature 461 (7262), 399-401, 2009 | 4533 | 2009 |
| Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen, M Ogishi, ... Science 370 (6515), eabd4570, 2020 | 2213 | 2020 |
| A whole-genome association study of major determinants for host control of HIV-1 J Fellay, KV Shianna, D Ge, S Colombo, B Ledergerber, M Weale, ... science 317 (5840), 944-947, 2007 | 1507 | 2007 |
| Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus AJ Thompson, AJ Muir, MS Sulkowski, D Ge, J Fellay, KV Shianna, ... Gastroenterology 139 (1), 120-129. e18, 2010 | 964 | 2010 |
| Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study J Fellay, C Marzolini, ER Meaden, DJ Back, T Buclin, JP Chave, ... The Lancet 359 (9300), 30-36, 2002 | 848 | 2002 |
| COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation S Marcel, AL Christian, N Richard, S Silvia, H Emma, F Jacques, Z Marcel, ... Swiss medical weekly 150, w202205, 2020 | 612 | 2020 |
| ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C J Fellay, AJ Thompson, D Ge, CE Gumbs, TJ Urban, KV Shianna, LD Little, ... Nature 464 (7287), 405-408, 2010 | 552 | 2010 |
| Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study J Fellay, B Ledergerber, E Bernasconi, H Furrer, M Battegay, B Hirschel, ... The Lancet 358 (9290), 1322-1327, 2001 | 490 | 2001 |
| Common genetic variation and the control of HIV-1 in humans J Fellay, D Ge, KV Shianna, S Colombo, B Ledergerber, ET Cirulli, ... PLoS genetics 5 (12), e1000791, 2009 | 478 | 2009 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 477 | 2021 |
| IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C TJ Urban, AJ Thompson, SS Bradrick, J Fellay, D Schuppan, KD Cronin, ... Hepatology 52 (6), 1888-1896, 2010 | 465 | 2010 |
| A global scientific strategy to cure hepatitis B PA Revill, FV Chisari, JM Block, M Dandri, AJ Gehring, H Guo, J Hu, ... The lancet Gastroenterology & hepatology 4 (7), 545-558, 2019 | 442 | 2019 |
| Influence of HLA-C expression level on HIV control R Apps, Y Qi, JM Carlson, H Chen, X Gao, R Thomas, Y Yuki, ... Science 340 (6128), 87-91, 2013 | 404 | 2013 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 356 | 2021 |
| Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection C Csajka, C Marzolini, K Fattinger, LA Décosterd, J Fellay, A Telenti, ... Clinical pharmacology & therapeutics 73 (1), 20-30, 2003 | 344 | 2003 |
| Privacy in the genomic era M Naveed, E Ayday, EW Clayton, J Fellay, CA Gunter, JP Hubaux, ... ACM Computing Surveys (CSUR) 48 (1), 1-44, 2015 | 336 | 2015 |
| HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C R Thomas, R Apps, Y Qi, X Gao, V Male, C O'huigin, G O'Connor, D Ge, ... Nature genetics 41 (12), 1290-1294, 2009 | 327 | 2009 |
| Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors E Patin, M Hasan, J Bergstedt, V Rouilly, V Libri, A Urrutia, C Alanio, ... Nature immunology 19 (3), 302-314, 2018 | 266 | 2018 |
| A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection JL Casanova, HC Su, L Abel, A Aiuti, S Almuhsen, AA Arias, P Bastard, ... Cell 181 (6), 1194-1199, 2020 | 259 | 2020 |
| Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction AJ Thompson, J Fellay, K Patel, HL Tillmann, S Naggie, D Ge, TJ Urban, ... Gastroenterology 139 (4), 1181-1189. e2, 2010 | 226 | 2010 |
David B. GoldsteinColumbia University在 columbia.edu 的电子邮件经过验证
